Connection
Martin Zamora to Cytomegalovirus Infections
This is a "connection" page, showing publications Martin Zamora has written about Cytomegalovirus Infections.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.782 |
|
|
|
-
Kiser TH, Fish DN, Zamora MR. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. J Heart Lung Transplant. 2012 Feb; 31(2):159-66.
Score: 0.339
-
Zamora MR. DNA viruses (CMV, EBV, and the herpesviruses). Semin Respir Crit Care Med. 2011 Aug; 32(4):454-70.
Score: 0.328
-
Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011 Apr; 43(3 Suppl):S1-S17.
Score: 0.319
-
Zamora MR, Davis RD, Leonard C. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation. 2005 Jul 27; 80(2):157-63.
Score: 0.216
-
Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor T, Grazia T, Weill D. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant. 2004 Oct; 4(10):1635-42.
Score: 0.204
-
Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant. 2004 Aug; 4(8):1219-26.
Score: 0.201
-
Zamora MR. Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant. 2002 Aug; 21(8):841-9.
Score: 0.175